New study investigates blood clot risks in Kids' leukemia treatment
NCT ID NCT07071051
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study looks at how the chemotherapy drug calaspargase pegol (Cal-PEG) affects blood clotting in children with acute lymphoblastic leukemia (ALL). Researchers will take blood samples before and after treatment to measure changes in coagulation. The goal is to better understand and manage clotting side effects in young patients.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACUTE LYMPHOBLASTIC LEUKEMIA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Email: •••••@•••••
Locations
-
Mayo Clinic in Rochester
RECRUITINGRochester, Minnesota, 55905, United States
Contact Email: •••••@•••••
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can a Low-Dose antifungal shield vulnerable patients from deadly fungal infections?
- Can a gentler chemo prep make stem cell transplants safer for blood cancer patients?
- A simple blood test may reveal hidden infertility risk in young cancer survivors
- Can donor immune cells tame stem cell transplant risks?
- A simple blood draw could spare kids with leukemia from painful bone marrow tests
- Can a smart drug missile tame Hard-to-Treat leukemia?